Home > Newsletters > FDAnews Drug Daily Bulletin > Pipeline Woes, Trial Problems Strike Sanofi, Ipsen, Eisai
FDAnews Drug Daily Bulletin
July 18, 2012 | Vol. 9 No. 140
Pipeline Woes, Trial Problems Strike Sanofi, Ipsen, Eisai
Sanofi, Ipsen and Eisai all took pipeline hits last week, with late-stage setbacks including Sanofi’s withdrawal of marketing applications for a blood-clot drug, Ipsen’s clinical hold for an investigational hemophilia drug and Eisai’s failed breast cancer trial. Sanofi withdrew all global applications for blood-clot drug semuloparin following comments from regulatory authorities, company spokeswoman Lauren Rose said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.